ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

A stalled Santa Claus rally has investors rotating to stability, spotlighting low-leverage names like Resmed that may hold up better amid tech-led volatility.

Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.

Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.

Perigon Wealth Management LLC increased its stake in shares of ResMed Inc. (NYSE: RMD) by 9.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 24,482 shares of the medical equipment provider's stock after purchasing an additional 2,110 shares during the period. Perigon Wealth Management

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Addenda Capital Inc. grew its holdings in ResMed Inc. (NYSE: RMD) by 41.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 77,456 shares of the medical equipment provider's stock after buying an additional 22,741 shares during the period. Addenda Capital Inc. owned 0.05% of ResMed

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA.

First Trust Advisors LP raised its holdings in shares of ResMed Inc. (NYSE: RMD) by 3.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,610 shares of the medical equipment provider's stock after purchasing an additional 3,390 shares during the

Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.